Safety and Feasibility of Performing Pericardiocentesis on Patients with Significant Pulmonary Hypertension.

MedStar author(s):
Citation: Cardiovascular Revascularization Medicine. 20(12):1090-1095, 2019 Dec.PMID: 31870527Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Pericardial Effusion/su [Surgery] | *Pericardiocentesis | *Pulmonary Arterial Hypertension/co [Complications] | Adult | Aged | Aged, 80 and over | Feasibility Studies | Female | Hemodynamics | Humans | Male | Middle Aged | Patient Safety | Pericardial Effusion/dg [Diagnostic Imaging] | Pericardial Effusion/et [Etiology] | Pericardial Effusion/pp [Physiopathology] | Pericardiocentesis/ae [Adverse Effects] | Pulmonary Arterial Hypertension/dg [Diagnostic Imaging] | Pulmonary Arterial Hypertension/pp [Physiopathology] | Retrospective Studies | Risk Assessment | Risk Factors | Severity of Illness Index | Treatment Outcome | Ventricular Function, RightYear: 2019Local holdings: Available in print through MWHC library: 2002 - presentISSN:
  • 1878-0938
Name of journal: Cardiovascular revascularization medicine : including molecular interventionsAbstract: BACKGROUND/PURPOSE: Pericardial effusion (PE) is a complication of pulmonary hypertension (PHT) and, specifically, pulmonary arterial hypertension (PAH), that confers a worse prognosis. The safety of performing pericardiocentesis in patients with PHT has not been established. We aimed to assess the safety and feasibility of performing pericardiocentesis in patients with significant PHT.CONCLUSIONS: Pericardiocentesis is a safe procedure, including in patients with significant PHT, including those with WHO Group I PAH. We advocate the use of invasive hemodynamic monitoring in patients with significant PHT.METHODS/MATERIALS: We performed a retrospective analysis from August 2013 to December 2018 at our tertiary-care center of patients who underwent a pericardiocentesis procedure. Patients, procedure, echocardiographic findings, any major intraprocedural complications, and post-procedural related complications up to 30days were recorded. Specifically, we studied patients with significant PHT.RESULTS: The cohort included 170 patients, with an average age of 62.6years and an even distribution of gender and co-morbidities. The etiology for the PE varied. Major complications were rare (1.7%) and only 10 patients (5.9%) required re-intervention for reaccumulation of fluid. There were 27 patients (15.9%) with significant PHT, 5 with World Health Organization (WHO) Group I PAH (2.94%). In the entire cohort, there were only 3 major complications (1.7%), none among PHT patients.SUMMARY: Pericardiocentesis tends to be a safe procedure. However, the safety of performing pericardiocentesis in patients with significant pulmonary hypertension has not been well established. We aimed to assess the safety and feasibility of performing pericardiocentesis, and specifically in patients with significant PHT out our tertiary center by performing a retrospective analysis. Copyright (c) 2019 Elsevier Inc. All rights reserved.All authors: Ben-Dor I, Case BC, Forrestal BJ, Hashim H, Kagan CM, Medvedofsky D, Rogers T, Satler LF, Tariq MU, Waksman R, Yang M, Yerasi COriginally published: Cardiovascular Revascularization Medicine. 20(12):1090-1095, 2019 Dec.Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2020-01-03
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31870527 Available 31870527

Available in print through MWHC library: 2002 - present

BACKGROUND/PURPOSE: Pericardial effusion (PE) is a complication of pulmonary hypertension (PHT) and, specifically, pulmonary arterial hypertension (PAH), that confers a worse prognosis. The safety of performing pericardiocentesis in patients with PHT has not been established. We aimed to assess the safety and feasibility of performing pericardiocentesis in patients with significant PHT.

CONCLUSIONS: Pericardiocentesis is a safe procedure, including in patients with significant PHT, including those with WHO Group I PAH. We advocate the use of invasive hemodynamic monitoring in patients with significant PHT.

METHODS/MATERIALS: We performed a retrospective analysis from August 2013 to December 2018 at our tertiary-care center of patients who underwent a pericardiocentesis procedure. Patients, procedure, echocardiographic findings, any major intraprocedural complications, and post-procedural related complications up to 30days were recorded. Specifically, we studied patients with significant PHT.

RESULTS: The cohort included 170 patients, with an average age of 62.6years and an even distribution of gender and co-morbidities. The etiology for the PE varied. Major complications were rare (1.7%) and only 10 patients (5.9%) required re-intervention for reaccumulation of fluid. There were 27 patients (15.9%) with significant PHT, 5 with World Health Organization (WHO) Group I PAH (2.94%). In the entire cohort, there were only 3 major complications (1.7%), none among PHT patients.

SUMMARY: Pericardiocentesis tends to be a safe procedure. However, the safety of performing pericardiocentesis in patients with significant pulmonary hypertension has not been well established. We aimed to assess the safety and feasibility of performing pericardiocentesis, and specifically in patients with significant PHT out our tertiary center by performing a retrospective analysis. Copyright (c) 2019 Elsevier Inc. All rights reserved.

English

Powered by Koha